^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | mirdametinib (PD-0325901) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PI3K pathway dependencies in endometrioid endometrial cancer cell lines
Excerpt:
Five cell lines (21%) were sensitive to the MEK inhibitor PD0325901, and response was significantly associated with the presence of KRAS, HRAS or NRAS mutations (P=0.028) but not with the doubling time of cells (mean sensitive 30.76 ± 0.90h, mean resistant 39.88 ± 4.45h, MWU, P= 0.743).
DOI:
10.1158/1078-0432.CCR-12-3815
